Meeting
2019 ASCO Annual Meeting
Phase I-II open label multicenter study of PD0332991 in BRAFV600mut metastatic melanoma patients harboring CDKN2A loss and RB1 expression and treated with vemurafenib.
Authors
Baptiste Louveau
Department of Pharmacogenomics, Saint Louis Hospital, APHP, Paris, France
Baptiste Louveau , Matthieu Resche-Rigon , Thierry Lesimple , Marc Pracht , Barouyr Baroudjian , Julie Delyon , Fanelie Jouenne , Mona Amini-Adle , Caroline Dutriaux , Laetitia Da Meda , Zineb Ghrieb , Didier Bouton , Annick Tibi , Samuel Huguet , Keyvan Rezai , Maxime Battistella , Samia Mourah , Celeste Lebbe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02202200
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9545)
DOI
10.1200/JCO.2019.37.15_suppl.9545
Abstract #
9545
Poster Bd #
116
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Genomic alterations in appendiceal carcinoma using circulating DNA.
First Author: Walid Labib Shaib
Poster
2016 ASCO Annual Meeting
Co-targeting BRAF with mTOR inhibition in solid tumors harboring BRAF mutations: A phase I study.
First Author: Shiraj Sen
Poster
2023 ASCO Annual Meeting
Abemaciclib in recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) harboring CDKN2A loss, and/or CCND1 and/or CDK6 amplification: A phase II multicenter trial.
First Author: Jerome Fayette
Poster
2022 ASCO Annual Meeting
Molecular alterations associated with rapid progression following CDK4/6 inhibitors (CDKi) in metastatic hormone receptor–positive breast cancer (mHRBC).
First Author: Malinda T West